Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source

Source document· March 26, 2026

Resolutions from the Annual General Meeting of Novo Nordisk A/S

View original at finance.yahoo.com

Resolutions from the Annual General Meeting of Novo Nordisk A/S Novo Nordisk A/S Bagsværd, Denmark, 26 March 2026 – Today, Novo Nordisk A/S held its Annual General Meeting…

Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

Novo Nordisk is reshaping its traditional approach to patient care and market access, needing to meet patients where they are
60% confidence
The year ahead will test Novo Nordisk's determination and capabilities, but the company faces it with confidence
60% confidence
2025 was a year of profound transformation for Novo Nordisk
60% confidence
Novo Nordisk's renewed focus, strengthened competencies and commitment to people with serious chronic diseases position them well for challenges and opportunities ahead
60% confidence

Data points we hold from this source

Novo Nordisk A/S · final dividend per share	7.95 DKK
Novo Nordisk A/S · dividend per share	11.70 DKK
Novo Nordisk A/S · share par value	0.10 DKK
Novo Nordisk A/S · authorized share repurchase limit	10 percent
Novo Nordisk A/S · authorized share capital increase	44650000 DKK
Novo Nordisk A/S · interim dividend per share	3.75 DKK